Skip to content
value.today
Trevena Inc. logo

Trevena Inc.

Formerly Parallex Therapeutics, Inc.

Total raised
$78 M
2 rounds on record
Latest round
$60 M
May 2013
First round on record
Jul 2010
Today
Went public
See the company page

Trevena Inc. is listed today as Trevena, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Trevena Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2013$60 MNo. 2$50 to $250 million

Trevena Inc.: Raise no. 2, May 2013

Investors in this round

9 investors had bought by the notice of May 17, 2013: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Trevena Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Includes shares of Common Stock issuable upon conversion of Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maxine Gowen · Executive Officer, Director
  • Christopher Mirabelli · Director
  • David Solomon · Director
  • Farah Champsi · Director
  • Lonnie Moulder, Jr. · Director
  • Robert Garland · Director
  • Terence McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maxine Gowen, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 17, 2013. Read the notice at the SEC.

equitySEC
Jul 2010$18 MNo. 1$10 to $50 million

Trevena Inc.: Raise no. 1, Jul 2010

Investors in this round

8 investors had bought by the notice of Jul 16, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Trevena Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $41 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Includes shares of Preferred Stock issuable upon exercise of warrants and shares of Common Stock issuable upon conversion of Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maxine Gowen · Executive Officer, Director
  • Christopher Mirabelli · Director
  • Farah Champsi · Director
  • Ralph Snyderman · Director
  • Robert Garland · Director
  • Robert, Jr. Ruffolo · Director
  • Terence McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maxine Gowen, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 16, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Trevena Inc. chose not to state its revenue in its newest notice of a funding round (May 2013).

    SEC Form D · May 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2013

That is all the official record says: Trevena Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Trevena Inc. are on record.

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Trevena Inc.
InvestorKindAmountRoundRoleSource
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
FL Holding C.V.Othernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
FLI International, LLCOthernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Forest Laboratories Holdings LtdCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Forest Laboratories IncCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
HealthCare Partners VIII, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
HealthCare Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
HealthCare Ventures VIII, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Nea 12 GP, LLCOthernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
NEA Partners 12, Limited PartnershipFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Enterprise Associates 12, Limited PartnershipFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Trevena Inc.
NameRoleNamed in
Maxine GowenExecutive officerMay 2013
Christopher MirabelliDirectorMay 2013
David SolomonDirectorMay 2013
Farah ChampsiDirectorMay 2013
Lonnie Moulder, Jr.DirectorMay 2013
Maxine GowenDirectorMay 2013
Robert GarlandDirectorMay 2013
Terence McGuireDirectorMay 2013
Ralph SnydermanDirectorJul 2010
Robert, Jr. RuffoloDirectorJul 2010

About

Biopharmaceutical company.

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.